EML4-ALK 阳性伴颅内转移的卵巢癌对劳拉替尼有反应：病例报告及文献综述
EML4-ALK-Positive Ovarian Cancer With Intracranial Metastasis Responds to Lorlatinib: A Case Report and Literature Review.
作者信息
Li Qiongqian, Cai Tongze, Zheng Xiaoming, Zhang Shunrong, Li Chanjuan, Tang Huang, Yu Zhiyong, Zhou Jianlong
机构信息
Department of Oncology Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine Guangxi China.
出版信息
Clin Case Rep. 2025 Jan 7;13(1):e70043. doi: 10.1002/ccr3.70043. eCollection 2025 Jan.
We report a case showing that lorlatinib is effective in treating EML4-ALK-positive low-grade serous ovarian cancer (LGSO) with intracranial metastasis. This may be the first clinical evidence of LGSO benefit from ALK inhibitors, to provide evidence for the use of ALK inhibitors in more ovarian cancer patients with EML4-ALK fusion and promoting new ideas for the study of EML4-ALK targets in ovarian cancer.
我们报告了一例显示劳拉替尼对治疗伴有颅内转移的EML4-ALK阳性低级别浆液性卵巢癌（LGSO）有效的病例。这可能是LGSO受益于ALK抑制剂的首个临床证据，为更多EML4-ALK融合的卵巢癌患者使用ALK抑制剂提供依据，并为卵巢癌中EML4-ALK靶点的研究推动新思路。
Zotero 插件